Terms: = Prostate cancer AND PRKAR1A, DKFZp779L0468, 5573, ENSG00000108946, PRKAR1, P10644, CNC1, PKR1, MGC17251, PPNAD1, TSE1, CNC, CAR
222 results:
1. A novel type-2 innate lymphoid cell-based immunotherapy for cancer.
Saranchova I; Xia CW; Besoiu S; Finkel PL; Ellis SLS; Kari S; Munro L; Pfeifer CG; Fazli L; Gleave ME; Jefferies WA
Front Immunol; 2024; 15():1317522. PubMed ID: 38524132
[TBL] [Abstract] [Full Text] [Related]
2. The impact of transportation mode, socioeconomic deprivation and rurality on travel times to radiotherapy and surgical services for patients with prostate cancer: A national population-based evaluation.
Han L; Sullivan R; Tree A; Lewis D; Price P; Sangar V; van der Meulen J; Aggarwal A
Radiother Oncol; 2024 Mar; 192():110092. PubMed ID: 38219910
[TBL] [Abstract] [Full Text] [Related]
3. Comparative Evaluation of STEAP1 Targeting Chimeric Antigen Receptors with Different Costimulatory Domains and Spacers.
Jin Y; Dunn C; Persiconi I; Sike A; Skorstad G; Beck C; Kyte JA
Int J Mol Sci; 2024 Jan; 25(1):. PubMed ID: 38203757
[TBL] [Abstract] [Full Text] [Related]
4. Exploring preventive care practices among unvaccinated individuals in the United States during the COVID-19 pandemic.
Filipas DK; Labban M; Beatrici E; Stone BV; Qian Z; D Andrea V; Ludwig TA; Reis LO; Cole AP; Trinh QD
Vaccine; 2024 Jan; 42(3):441-447. PubMed ID: 38184391
[TBL] [Abstract] [Full Text] [Related]
5. Multicenter development of a PET-based risk assessment tool for product-specific outcome prediction in large B-cell lymphoma patients undergoing car T-cell therapy.
Voltin CA; Paccagnella A; Winkelmann M; Heger JM; Casadei B; Beckmann L; Herrmann K; Dekorsy FJ; Kutsch N; Borchmann P; Fanti S; Kunz WG; Subklewe M; Kobe C; Zinzani PL; Stelljes M; Roth KS; Drzezga A; Noppeney R; Rahbar K; Reinhardt HC; von Tresckow B; Seifert R; Albring JC; Blumenberg V; Farolfi A; Flossdorf S; Gödel P; Hanoun C
Eur J Nucl Med Mol Imaging; 2024 Apr; 51(5):1361-1370. PubMed ID: 38114616
[TBL] [Abstract] [Full Text] [Related]
6. [Current Trend of car-T Cell Therapy for Metastatic Castration-Resistant prostate cancer].
Takahashi S
Gan To Kagaku Ryoho; 2023 Oct; 50(10):1038-1042. PubMed ID: 38035830
[TBL] [Abstract] [Full Text] [Related]
7. Noninvasive longitudinal PET/CT imaging of car T cells using PSMA reporter gene.
Song X; Zhang Y; Lv X; Xu Z; Long Y; Gai Y; Jiang D; Lei P; Lan X
Eur J Nucl Med Mol Imaging; 2024 Mar; 51(4):965-977. PubMed ID: 37971500
[TBL] [Abstract] [Full Text] [Related]
8. Antitumor activity of AZD0754, a dnTGFβRII-armored, STEAP2-targeted car-T cell therapy, in prostate cancer.
Zanvit P; van Dyk D; Fazenbaker C; McGlinchey K; Luo W; Pezold JM; Meekin J; Chang CY; Carrasco RA; Breen S; Cheung CS; Endlich-Frazier A; Clark B; Chu NJ; Vantellini A; Martin PL; Hoover CE; Riley K; Sweet SM; Chain D; Kim YJ; Tu E; Harder N; Phipps S; Damschroder M; Gilbreth RN; Cobbold M; Moody G; Bosco EE
J Clin Invest; 2023 Nov; 133(22):. PubMed ID: 37966111
[TBL] [Abstract] [Full Text] [Related]
9. [Metastatic castration-resistant prostate cancer-emerging trends in therapy].
von Amsberg G; Todenhöfer T
Urologie; 2023 Dec; 62(12):1289-1294. PubMed ID: 37955661
[TBL] [Abstract] [Full Text] [Related]
10. Construction of truncated PSMA as a PET reporter gene for car T cell trafficking.
Zhang Y; Song X; Xu Z; Lv X; Long Y; Lan X; Lei P
J Leukoc Biol; 2024 Feb; 115(3):476-482. PubMed ID: 37943840
[TBL] [Abstract] [Full Text] [Related]
11. Disruption of SUV39H1-Mediated H3K9 Methylation Sustains car T-cell Function.
Jain N; Zhao Z; Koche RP; Antelope C; Gozlan Y; Montalbano A; Brocks D; Lopez M; Dobrin A; Shi Y; Gunset G; Giavridis T; Sadelain M
Cancer Discov; 2024 Jan; 14(1):142-157. PubMed ID: 37934007
[TBL] [Abstract] [Full Text] [Related]
12. Strategies for modifying the chimeric antigen receptor (car) to improve safety and reduce toxicity in car T cell therapy for cancer.
Sayadmanesh A; Yekehfallah V; Valizadeh A; Abedelahi A; Shafaei H; Shanehbandi D; Basiri M; Baradaran B
Int Immunopharmacol; 2023 Dec; 125(Pt A):111093. PubMed ID: 37897950
[TBL] [Abstract] [Full Text] [Related]
13. Untargeted lipidomics reveal association of elevated plasma C18 ceramide levels with reduced survival in metastatic castration-resistant prostate cancer patients.
Cattrini C; Manfredi M; Barboro P; Ghirimoldi M; Mennitto A; Martini V; Battioni A; Le Van M; Gobbato S; Branni C; Ayed RB; Pinato DJ; Catalano F; Zanardi E; Boccardo F; Gennari A
Sci Rep; 2023 Oct; 13(1):17791. PubMed ID: 37853018
[TBL] [Abstract] [Full Text] [Related]
14. Emerging Immunotherapy Approaches for Treating prostate cancer.
Meng L; Yang Y; Mortazavi A; Zhang J
Int J Mol Sci; 2023 Sep; 24(18):. PubMed ID: 37762648
[TBL] [Abstract] [Full Text] [Related]
15. prostate cancer immunotherapy: Improving clinical outcomes with a multi-pronged approach.
Sridaran D; Bradshaw E; DeSelm C; Pachynski R; Mahajan K; Mahajan NP
Cell Rep Med; 2023 Oct; 4(10):101199. PubMed ID: 37738978
[TBL] [Abstract] [Full Text] [Related]
16. F77 antigen is a promising target for adoptive T cell therapy of prostate cancer.
Grover P; Nunez-Cruz S; Leferovich J; Wentz T; Bagchi A; Milone MC; Greene MI
Biochem Biophys Res Commun; 2023 Nov; 680():51-60. PubMed ID: 37717341
[TBL] [Abstract] [Full Text] [Related]
17. Pre-clinical validation of a pan-cancer car-T cell immunotherapy targeting nfP2X7.
Bandara V; Foeng J; Gundsambuu B; Norton TS; Napoli S; McPeake DJ; Tyllis TS; Rohani-Rad E; Abbott C; Mills SJ; Tan LY; Thompson EJ; Willet VM; Nikitaras VJ; Zheng J; Comerford I; Johnson A; Coombs J; Oehler MK; Ricciardelli C; Cowin AJ; Bonder CS; Jensen M; Sadlon TJ; McColl SR; Barry SC
Nat Commun; 2023 Sep; 14(1):5546. PubMed ID: 37684239
[TBL] [Abstract] [Full Text] [Related]
18. Tandem car-T cells targeting MUC1 and PSCA combined with anti-PD-1 antibody exhibit potent preclinical activity against non-small cell lung cancer.
Wang A; Lv T; Song Y
Cell Immunol; 2023; 391-392():104760. PubMed ID: 37660477
[TBL] [Abstract] [Full Text] [Related]
19. Low-dose carboplatin modifies the tumor microenvironment to augment car T cell efficacy in human prostate cancer models.
Porter LH; Zhu JJ; Lister NL; Harrison SG; Keerthikumar S; Goode DL; Urban RQ; Byrne DJ; Azad A; Vela I; Hofman MS; Neeson PJ; Darcy PK; Trapani JA; Taylor RA; Risbridger GP
Nat Commun; 2023 Sep; 14(1):5346. PubMed ID: 37660083
[TBL] [Abstract] [Full Text] [Related]
20. Self-removal of catheter after robot-assisted radical prostatectomy: a feasibility study.
Abou Chedid W; Carbin DD; Innes M; Casson H; Broe M; Hossain M; Frajkoulis G; Whiting D; Adamou C; Kusuma M; Moschonas D; Hicks J; Patil K; Eden C; Perry MJA
J Robot Surg; 2023 Dec; 17(6):2697-2701. PubMed ID: 37548820
[TBL] [Abstract] [Full Text] [Related]
[Next]
